Tianeptine: A Literature Course in Six Modules

This course walks through the published tianeptine literature one module at a time: what the compound is, how its mechanism has been described, what outcomes have been reported in cell and animal models, what adverse events appear in case reports and surveillance data, what formulation and pharmacokinetic work exists, and how regulators have classified it. Each module closes with the limits of the evidence, because the strength of a claim depends entirely on the design that produced it.

This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, symptoms, medication or treatment. Nothing here describes a protocol, and no study summarised below should be read as a statement about what any individual should do.

Module 1: What Tianeptine Is and How It Has Been Studied

Definition and chemical class

Tianeptine is a small molecule, not a peptide. It is a tricyclic-structured compound carrying a heptanoic acid side chain, and it has been described in the research literature as an antidepressant, including in a 2017 mouse study titled around "the antidepressant tianeptine" (PMID 28303899). A 2007 forensic case report referred to the marketed product by the trade name Stablon (PMID 17630235), reflecting its history as a prescription medicine in several countries.

Forms described in the literature

• Tianeptine sodium, immediate-release tablets — used as the reference formulation in a 2022 formulation study (PMID 35566178).
• Sustained-release dual-layer tablets — developed and characterised in that same 2022 in vitro–in vivo correlation study (PMID 35566178).
• Unapproved consumer products — nursing and public-health papers have described tianeptine appearing in products marketed outside the prescription channel in the United States (PMID 37276205, PMID 41084181).
• Analytical reference material — tianeptine and its degradation products have been profiled by mass spectrometry in environmental water samples (PMID 38849097).

The shape of the evidence base

The verified literature reviewed in this course spans six study types: in vitro neuronal cell work, rodent behavioural and tissue studies, drug-discrimination pharmacology, pharmaceutical formulation science, clinical case reports, and population-level poison-centre surveillance. Those designs answer very different questions, and none of them is a substitute for another.

Limits of the evidence (Module 1)

No randomised controlled efficacy trial appears in this verified set. That means this course can describe how tianeptine has been studied and what the cited papers reported, but it cannot characterise comparative clinical effectiveness, optimal use, or outcomes in any human population beyond the cases and surveillance data explicitly cited.

Module 2: Mechanism as Described in the Literature

Mu-opioid receptor involvement

The single most consequential mechanistic finding in this set comes from a 2017 mouse study reporting that tianeptine's antidepressant-like behavioural effects required the mu-opioid receptor, with those behavioural effects absent in mice lacking the receptor (PMID 28303899). Researchers framed tianeptine in that report as acting at the mu-opioid receptor rather than through the monoamine mechanisms historically attributed to it. Clinical and public-health papers later returned to this pharmacology when discussing dependence and withdrawal (PMID 37276205).

Interoceptive and discriminative stimulus effects

A 2006 psychopharmacology study used a drug-discrimination procedure to characterise the discriminative stimulus properties of tianeptine in animals (PMID 16292591). Drug discrimination is a behavioural assay in which animals learn to report an internal drug state; it is used to place a compound relative to reference drug classes rather than to measure therapeutic outcome.

Plasticity-related markers in cells

A 2014 study exposed SH-SY5Y human neuroblastoma cells to tianeptine and reported altered expression of NCAM140 and phosphorylated CREB, two markers linked in the literature to neuronal plasticity signalling (PMID 25110505). The study measured protein expression in a cell line, not behaviour or mood.

Synaptic architecture in a stress model

A 2021 rat study reported that tianeptine modulated synaptic vesicle dynamics and favoured synaptic mitochondrial processes in socially isolated animals (PMID 34493757). The endpoints were molecular and ultrastructural features of the synapse in a chronic social-isolation paradigm.

Limits of the evidence (Module 2)

Mechanism studies here were conducted in genetically modified mice, rats and an immortalised human cell line. Receptor-level and marker-level findings explain how a molecule might act; they do not demonstrate a clinical benefit, and a knockout-mouse result cannot be extrapolated to any human outcome. Direction and magnitude of marker changes should be read in the original papers rather than inferred from a summary.

Module 3: Reported Outcomes by Study

The table below compresses the model, the endpoint and the reported direction of each finding. Every entry is a summary of what researchers reported in that specific design.

An unexpected outcome domain

Not all reported outcomes concern mood or behaviour. The 2017 ovariectomised-rat study examined skeletal endpoints and reported anti-osteoporotic effects of tianeptine in that surgical model of oestrogen deficiency (PMID 28081469). This is a single preclinical report in a specific model and has no established clinical counterpart in the verified set.

Limits of the evidence (Module 3)

Every outcome in this module is preclinical. Animal antidepressant-like assays measure behaviour under laboratory conditions, not diagnosed illness; ovariectomised rats model one pathway to bone loss, not human osteoporosis in full. None of these studies reported human efficacy endpoints, durations of effect, or dose–response relationships that could be generalised, and this page therefore states no dose.

Module 4: Tianeptine Side Effects: What Studies Report

Withdrawal and dependence

A 2024 case report described tianeptine withdrawal as an easily obscured presentation, detailing how the syndrome appeared clinically and how it was managed in the reported case (PMID 39022455). A 2023 nursing paper addressed tianeptine use and misuse, discussing dependence, withdrawal and the implications for assessment and monitoring in clinical settings (PMID 37276205). Both papers noted that tianeptine is not captured by routine drug screening panels, which contributed to delayed recognition (PMID 39022455, PMID 37276205).

Poison-centre surveillance

A 2018 MMWR analysis characterised tianeptine exposures reported to the US National Poison Data System between 2000 and 2017 and reported an increase in exposure calls over that period, with clinical effects spanning neurologic, cardiovascular and gastrointestinal categories and frequent co-exposure to other substances (PMID 30070980). A 2025 analysis revisited the question of whether tianeptine products represent a broad public-health threat or a narrower niche pattern of use (PMID 41084181).

Fatal outcome reported

A 2007 forensic science report described a fatal intoxication involving tianeptine (Stablon), including the post-mortem analytical findings in that single case (PMID 17630235). Case reports establish that an outcome has occurred; they do not establish how often it occurs.

Limits of the evidence (Module 4)

Case reports and poison-centre data are uncontrolled. Surveillance systems capture calls, not population incidence, and depend on voluntary reporting; co-exposure to other substances complicates attribution (PMID 30070980). No controlled safety trial with systematic adverse-event ascertainment appears in this verified set, so no frequency, severity ranking or threshold can be drawn from it.

Module 5: Pharmacokinetics Where Data Exist

Formulation and in vitro–in vivo correlation

The clearest pharmacokinetic work in this set is a 2022 study that developed tianeptine sodium sustained-release dual-layer tablets and established an in vitro–in vivo correlation between tablet dissolution and the observed plasma concentration profile (PMID 35566178). The study's premise was that a modified-release design could change the release profile relative to conventional tianeptine sodium tablets, and the researchers used correlation modelling to link laboratory dissolution data to absorption behaviour (PMID 35566178).

Analytical chemistry and degradation

A 2024 study used non-targeted UHPLC-QTOF MS/MS to identify tianeptine photodegradation products in water samples (PMID 38849097). This is environmental fate and analytical identification work rather than human pharmacokinetics, but it matters for a practical reason: knowing which transformation products exist informs how a compound is detected and distinguished analytically.

Detection in clinical settings

Clinical papers in this set noted that tianeptine escapes standard immunoassay-based drug screens, so exposure may be missed unless specifically sought (PMID 39022455, PMID 37276205).

Limits of the evidence (Module 5)

This course states no half-life, clearance, bioavailability or plasma concentration values, because the verified papers' abstract-level scope does not supply parameters this page can responsibly reproduce. Formulation studies also describe a specific manufactured product under study conditions; results from one dosage form do not transfer to unregulated products of unknown composition.

Module 6: Regulatory Status, Stated Factually

Approved prescription products

Tianeptine has been marketed as a prescription antidepressant in a number of countries outside the United States, including under the Stablon trade name referenced in the 2007 forensic literature (PMID 17630235), and formulation research on tianeptine sodium tablets has been conducted within that pharmaceutical context (PMID 35566178).

United States status

Tianeptine is not an FDA-approved drug product in the United States. Nursing and public-health literature has described tianeptine instead appearing in unapproved consumer products and has discussed the regulatory and clinical response to those products (PMID 37276205, PMID 41084181). Because it is not a component of an approved US drug product, tianeptine does not sit within the pathways that pharmacies and outsourcing facilities use for compounding from approved active ingredients or listed bulk drug substances. Material distributed for laboratory work is typically labelled research-use-only, meaning it is designated for in vitro or animal research and not for human consumption.

Regulatory classification differs by country and, within the United States, has also been addressed at state level; the published analyses above discuss those responses in context (PMID 41084181). This section describes published regulatory facts and is not legal advice.

Limits of the evidence (Module 6)

Regulatory status changes, varies by jurisdiction, and is not a scientific finding. Approval in one country says nothing about safety or efficacy in another, and the absence of approval does not by itself describe a pharmacological property. Readers should check current primary regulatory sources rather than relying on a summary.

Closing: What the Studies Did Not Test

Reading this course as a whole, the gaps are as instructive as the findings:

• No randomised human efficacy trial appears in this verified set, so comparative effectiveness against any alternative was not tested.
• No human dose–response work is summarised here, which is why this page names no dose.
• Long-term human safety was not evaluated in a controlled design; the adverse-event literature cited is composed of case reports and surveillance data (PMID 30070980, PMID 39022455).
• Unregulated product composition was not characterised in the mechanistic studies, which used defined laboratory material rather than consumer products (PMID 41084181).
• Skeletal findings were not replicated clinically; the bone endpoints were reported in ovariectomised rats only (PMID 28081469).
• Interactions, pregnancy, paediatric and geriatric populations were not addressed in the studies summarised here.

Tianeptine is an unusual case in the literature: a compound with a long pharmaceutical history in some countries, a mechanism reframed by later receptor work (PMID 28303899), and a parallel body of toxicology and addiction-medicine reporting that grew from unregulated products (PMID 37276205). Understanding it requires holding all three strands at once, and reading the primary papers rather than any summary of them.

References

• NCAM140 and pCREB Expression after Tianeptine Treatment of SH-SY5Y Cells (Psychiatry Investigation, 2014)
• Tianeptine's Obscured Withdrawal, Presentation, and Treatment (Cureus, 2024)
• The Behavioral Effects of the Antidepressant Tianeptine Require the Mu-Opioid Receptor (Neuropsychopharmacology, 2017)
• In Vitro-In Vivo Correlation of Tianeptine Sodium Sustained-Release Dual-Layer Tablets (Molecules, 2022)
• Nursing Implications for Tianeptine Use and Misuse (Journal of Addictions Nursing, 2023)
• Anti-osteoporotic effects of an antidepressant tianeptine on ovariectomized rats (Biomedicine & Pharmacotherapy, 2017)
• Tianeptine modulates synaptic vesicle dynamics and favors synaptic mitochondria processes in socially isolated rats (Scientific Reports, 2021)
• Tianeptine Products: Public Health Threat or Niche Substance Use? (Journal of Psychoactive Drugs, 2025)
• Characteristics of Tianeptine Exposures Reported to the National Poison Data System - United States, 2000-2017 (MMWR, 2018)
• Fatal intoxication with tianeptine (Stablon) (Forensic Science International, 2007)
• Non-targeted identification of tianeptine photodegradation products in water samples by UHPLC-QTOF MS/MS (Chemosphere, 2024)
• Discriminative stimulus properties of tianeptine (Psychopharmacology, 2006)